Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date

ROS1 inhibition provides impressive survival benefits in ROS1-rearranged non-small cell lung cancer (NSCLC) patients. Crizotinib is the only tyrosine kinase inhibitor (TKI) approved by both FDA and EMA for the treatment of ROS1-positive lung cancer. In addition, several TKI have been tested with pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Facchinetti, Francesco, Friboulet, Luc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6747675/
https://www.ncbi.nlm.nih.gov/pubmed/31572036
http://dx.doi.org/10.2147/LCTT.S190786

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6747675/
https://www.ncbi.nlm.nih.gov/pubmed/31572036
http://dx.doi.org/10.2147/LCTT.S190786

Ejemplares similares